
XDC
The Bioconjugation Leader
YOUR FRONTIER TECHNOLOGY PLATFORM FOR
BIOCONJUGATES
Conjugation and Payload-Linker Technology Innovation
LEARN MORE

WuXi XDC
TECHNOLOGY PLATFORM

Turn Transformative Potential into Reality

From achieving optimal conjugation stability to ensuring precise payload delivery and minimizing off-target toxicity, every step of bioconjugate development demands cutting-edge solutions. WuXi XDC possesses deep expertise and extensive experience in conjugation. Leveraging our proprietary technologies, we have built a robust foundation for advanced bioconjugate development.

Beyond our internal capabilities, we are actively forging and expanding partnerships with leading industry players. Through these collaborations, we continuously enrich and refine our technology platform, positioning it as the premier destination for comprehensive, customized bioconjugate development solutions.



NOVEL CONJUGATION TECHNOLOGIES

WuXiDAR^{X}™

Conjugation technology targeting interchain cysteine sites delivers exceptional flexibility in DAR ratios.

X-LinC

A stable thiol-reactive connector overcomes maleimide instability.

CysLink

Stable thiol-rebridging connector

AbClick

Affinity peptide-assisted conjugation technology

In-House Proprietary

External Partnerships

ADVANCED PAYLOAD-LINKER TECHNOLOGIES



WuXiTecan

Novel Payload Linkers

Payload linkers strategically engineered to deliver enhanced therapeutic potential

A Powerful Technology Platform for ADCs and Diverse Bioconjugate Development

- Diverse conjugation strategy and payload linker options
- Redefine bioconjugate development efficiency and reliability



Versatile Drug-to-Antibody Ratio Options with WuXiDARx

Proprietary Conjugation Technology

WuXiDARx, our proprietary conjugation technology targeting the clinically validated interchain cysteine sites, delivers exceptional flexibility in drug-to-antibody ratio (DAR) and demonstrates high homogeneity. It is compatible with native IgG1 antibodies and a wide range of common payload linker and significantly simplifies the CMC process. The technology delivers significant value across the development continuum: When screening antibody and payload-linker combinations during discovery, it streamlines ADC engineering and facilitates optimal DAR identification. At the CMC stage, it accelerates development, mitigates risks, and reduces large-scale manufacturing costs.

Features and Advantages



Flexible DAR

- WuXiDAR1
- WuXiDAR2
- WuXiDAR4
- WuXiDAR6

Highly Homogenous ADC

- ≥ 85% (DAR1, DAR2) or ≥ 65% (DAR4, DAR6) a single conjugated species without column purification
- ≥ 95% with column purification

Compatible with Native mAbs

- No antibody engineering modification needed

Meeting Clients' Diversified Needs

- Compatible with common payload-linkers: MMAE, MMAF, DXD, PBD
- No connector modification needed

Simple CMC and Cost Savings

- Simple conjugation process
- Comparable COGs with conventional Cys random conjugation

* WuXiDARx was developed with BioReinno's MCLICK-DAR1-A1, MCLICK-DAR2-A1, and MCLICK-DAR6-A1 technologies.

Enable Versatility across Diversified Bioconjugates beyond Conventional ADCs

Dual-Payload ADC



4+4 format **4+2 format** **6+2 format**

WuXiDARx technology can be used to generate dual-payload ADCs using only the interchain cysteine sites.

BsADC



WuXiBody + WuXiDARx

AOC



Antibody oligonucleotide conjugates using **WuXiDAR1**

APC



AAntibody peptide conjugates using **WuXiDAR2**

Robust and Validated Conjugation Technology

WuXiDAR4

ADCs produced from WuXiDAR4 demonstrated comparable cytotoxicity to ADCs produced by conventional random conjugation methods, but demonstrate better pharmacokinetics (PK) profiles and tolerability. So far, 7 ADC molecules that WuXiDAR4 generated have entered clinical trials.

Improved Efficacy and Tolerability

WuXiDAR4 technology features an enhanced high-homogeneity DAR 4 profile. ADCs engineered with the technology demonstrate superior PK, *in vivo* efficacy, and safety profile relative to ADCs achieving DAR 4 via conventional random cysteine conjugation.



WuXiDAR4-ADC shows stronger *in vivo* efficacy (N87CDX)



WuXiDAR4-ADC shows better tolerability (C57BL/6 mice, single dose)

Simple and Robust CMC



10+
CMC projects

7
Clinical-stage ADC molecules

2+ kg
GMP batches prepared

Ideal for Your Antibody-Oligonucleotide Conjugates

WuXiDAR1

High Purity
Up to ~ 90% D1 species before column purification

Simple Process
Chemical conjugation, comparable with symmetrical antibody, no sequence engineering or enzymatic reaction required

Good Efficacy
Higher siRNA in target tissue and stronger DMPK silence efficiency in mouse





X-LinC
Novel Thiol Reactive Connector

The commonly employed maleimide-thiol conjugation in ADCs is susceptible to retro-Michael addition—a reversible reaction that leads to compromised efficacy and off-target toxicity. WuXi XDC addresses this inherent instability through our proprietary X-LinC connector technology. This innovative solution has demonstrated superior plasma stability, high conjugation efficiency, and seamless compatibility with WuXiDARx.

Superior stability

Maintain ADC stability with minimal payload release in circulation.



Fast reaction kinetics

Enable fast and efficient conjugation.



Better toxicity tolerance



CysLink
Thiol-Rebridging Connector

Advantages

Superior stability:
Forms robust conjugation, ensuring ADC stability and controlled drug release while minimizing toxicity.

Fully compatible with WuXiDARx

Reduced half antibody ratio:
Enhances homogeneity, optimizing conjugation efficiency for more effective therapies.



Advanced Payload-Linker Technologies

Our advanced payload-linker technologies are strategically engineered to maximize therapeutic potential through 3 core innovations:

- Tunable payload potency balancing efficacy and safety
- Novel cleavage mechanisms enabling controlled drug release
- Hydrophilicity-optimized linkers engineered to enhance safety



A diverse portfolio of advanced payload-linkers engineered for safety, efficacy, and flexibility across development stages

	Design Strategy		Connector	Release Mechanism	Payload	Stage
WuXiTecan-1 Source: WuXi XDC	Novel TOPi payload with GGFG linker		Mal	Peptidase (Lysosomal)	Novel payload	Preclinical
	Efficacy	• Payload efficacy is comparable to DXd • WuXiTecan-1 ADC efficacy is comparable to DS-8201 in CDX model				
	Safety	• WuXiTecan-1 ADC is better tolerated than DS-8201 in acute mice toxicity study • WuXiTecan-1 ADC is well tolerated in cyno pre-tox at 55 mpk Q3W*3				

	Design Strategy and Advantages		Connector	Release Mechanism	Payload	Stage
WuXiTecan-2 Source: WuXi XDC	Exatecan with novel hydrophilic linker		Mal	Peptidase (Lysosomal)	Exatecan	Preclinical
	Hydrophilicity	• Better hydrophilicity compared to benchmark*				
	Efficacy	• WuXiTecan-2 ADC shows similar or better efficacy compared to benchmarks* in the CDX model				
	Safety	• WuXiTecan-2 ADC is well tolerated in acute mice toxicity study compared to benchmark* • WuXiTecan-2 ADC is well tolerated in cyno pre-tox at 45 mpk Q3W*3				

*Benchmark: Exatecan with hydrophilic linkers that showed promising results in clinical trials

	Design Strategy and Advantages	Connector	Release Mechanism	Payload	Stage
T-moiety-Exatecan Source: Partner	Exatecan with novel hydrophilic linker	Mal	Peptidase (Lysosomal)	Exatecan	Phase I
OHPAS-Nexatecan Source: Partner	Novel payload and self-immolative adaptor	Mal/IAA	Glucuronidase (Lysosomal)	Nexatecan	CMC
UniLinker-Exatecan Source: Partner	Exatecan with novel TME release linker	Mal	Peptidase (Lysosomal and TME)	Exatecan	CMC

About WuXi XDC

WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody and other bioconjugate intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.

Your Single-Source for Bioconjugation Development and cGMP Manufacturing

wuxixdc.com | wuxixdc_info@wuxibiologics.com

XDC The Bioconjugation Leader

8-8-2025